Literature DB >> 7692132

Angiogenic growth factor and revascularization of the ischemic limb: evaluation in a rabbit model.

L Q Pu1, A D Sniderman, Z Arekat, A M Graham, R Brassard, J F Symes.   

Abstract

We have previously shown that administration of endothelial cell growth factor (ECGF) significantly accelerates revascularization in the ischemic rabbit hindlimb model. Nevertheless, much remains to be learned as to the effectiveness and limitations of this approach. The present study was designed, therefore, to determine whether a dose-response relationship could be demonstrated for this agent, whether it was effective if systemically administered, and finally, whether it affected vascularization in a nonischemic limb. Our established unilateral ischemic rabbit hindlimb model and ECGF administration protocol were used to examine these questions. Three groups of animals were studied to determine a dose-response relationship of ECGF in the ischemic limb. Revascularization was assessed by measurement of calf blood left to right (L/R) pressure ratio before (Day 0) and after ECGF injections (Days 1, 10, and 20) and quantitative vascularization was assessed by angiography at Day 20 when the study was terminated. The results of the dose-response study were [formula: see text] Two other groups of animals were also studied. In Group 4, intramuscular ECGF was injected in the left front limb remote from the ischemic hindlimb and in Group 5 it was injected into the left hindlimb of a normal animal. In neither group was any significant effect on vascularization evident. Thus, our data suggest that the relationship of ECGF and revascularization of the ischemic limb is dose dependent and is demonstrable only when it is administered directly into the limb in the presence of ischemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692132     DOI: 10.1006/jsre.1993.1088

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

Review 1.  Tissue Engineering of the Microvasculature.

Authors:  Joe Tien
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

2.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.

Authors:  Y Kureishi; Z Luo; I Shiojima; A Bialik; D Fulton; D J Lefer; W C Sessa; K Walsh
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

3.  Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform.

Authors:  N Kipshidze; V Chekanov; P Chawla; L R Shankar; J B Gosset; K Kumar; D Hammen; J Gordon; M H Keelan
Journal:  Tex Heart Inst J       Date:  2000

Review 4.  Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease.

Authors:  Joaquin De Haro; Francisco Acin; Alfonso Lopez-Quintana; Aurora Florez; Esther Martinez-Aguilar; Cesar Varela
Journal:  Heart Vessels       Date:  2009-09-27       Impact factor: 2.037

5.  Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth.

Authors:  Akihiro Takahashi; Yasuko Kureishi; Jiang Yang; Zhengyu Luo; Kun Guo; Debabrata Mukhopadhyay; Yuri Ivashchenko; Didier Branellec; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.